Imunon (IMNN) risk factors

33 risks, 2 dropped, 6 reworded since the prior year. Accumulated deficit rose to $421 million as net losses continued at $14.5 million in 2025. Financial disclosures updated figures for accumulated deficit and annual net losses.

35 risks. Imunon faces substantial going concern doubt with an accumulated deficit of $407 million as of December 31, 2024. Drug development relies entirely on third-party manufacturers, clinical investigators, and licensed technologies like Duke University's thermo-sensitive liposome technology. Commercial success depends heavily on regulatory milestones for IMNN-001, including FDA Fast Track and Orphan Drug designations.